Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/51424
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12658]
Metadatos
Mostrar el registro completo del ítem
THE VARIANTS QUESTION: WHAT IS THE PROBLEM?
Pandemia
SARS‐CoV‐2
Vacina
Variantes de preocupações
Variantes de interesses
Autor
Afiliación
University of Maryland School of Medicine. Institute of Human Virology and Global Virus Network Center. Department of Biochemistry and Molecular Biology. Baltimore, Maryland, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Belo Horizonte, MG, Brasil.
University of Maryland School of Medicine. Institute of Human Virology and Global Virus Network Center. Department of Biochemistry and Molecular Biology. Baltimore, Maryland, USA.
University Campus Bio‐Medico of Rome. Area Comunicazione e Brand Management. Rome, Italy.
University Campus Bio‐Medico of Rome. Department of Diagnostic and Therapeutic Medicine. Rome, Italy.
Campus Bio‐Medico University. Department of Gastrointestinal Diseases. Rome, Italy.
University Campus Bio‐Medico of Rome. Unit of Clinical Laboratory Science. Rome, Italy.
University of Biomedical Campus. Medical Statistic and Molecular Epidemiology Unit. Rome, Italy.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Belo Horizonte, MG, Brasil.
University of Maryland School of Medicine. Institute of Human Virology and Global Virus Network Center. Department of Biochemistry and Molecular Biology. Baltimore, Maryland, USA.
University Campus Bio‐Medico of Rome. Area Comunicazione e Brand Management. Rome, Italy.
University Campus Bio‐Medico of Rome. Department of Diagnostic and Therapeutic Medicine. Rome, Italy.
Campus Bio‐Medico University. Department of Gastrointestinal Diseases. Rome, Italy.
University Campus Bio‐Medico of Rome. Unit of Clinical Laboratory Science. Rome, Italy.
University of Biomedical Campus. Medical Statistic and Molecular Epidemiology Unit. Rome, Italy.
Resumen en ingles
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) originated in Wuhan, China in early December 2019 has rapidly widespread worldwide. Over the course of the pandemic, due to the advance of whole‐genome sequencing technologies, an unprecedented number of genomes have been generated, providing both invaluable insights into the ongoing evolution and epidemiology of the virus and allowing the identification of hundreds of circulating genetic variants during the pandemic. In recent months variants of SARS‐CoV‐2 that have an increased number of mutations on the Spike protein have brought concern all over the world. These have been called “variants of concerns” (VOCs), and/or “variants of interests” (VOIs) as it has been suggested that their genome mutations might impact transmission, immune control, and virulence. Tracking the spread of emerging SARS‐CoV‐2 variants is crucial to inform public health efforts and control the ongoing pandemic. In this review, a concise characterization of the SARS‐CoV‐2 mutational patterns of the main VOCs and VOIs circulating and cocirculating worldwide has been presented to determine the magnitude of the SARS‐CoV‐2 threat to better undersunderstand the virus genetic diversity and its potential impact on vaccination strategy.
Palabras clave en portugues
Estratégias de intervençãoPandemia
SARS‐CoV‐2
Vacina
Variantes de preocupações
Variantes de interesses
Compartir